Author:
Carr Warner W.,Jain Neal,Sublett J. Wesley
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference121 articles.
1. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15:1–9.
2. Frevert J, Dressler D. Clinical relevance of immunoresistance to botulinum therapy. In: Rosales RL, Dressler D, editors. Botulinum toxin therapy manual for dystonia and spasticity. IntechOpen; 2016. p. 33–49.
3. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92:e48–54.
4. Srinoulprasert Y, Wanitphakdeedecha R. Antibody-induced botulinum toxin treatment failure: a review and novel management approach. J Cosmet Dermatol. 2020;19:2491–6.
5. Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res. 2016;29:105–17.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献